Skip to main content
Erschienen in:

08.03.2024 | Original article

Left ventricular hypertrophy and left atrial diameter are associated with mortality risk in haemodialysis patients: a retrospective cohort study

verfasst von: Jiuxu Bai, Wanqing Huang, Yanping Zhang, Lin Wei, Chen Zhao, Zhuo Ren, Qian Wang, Kaiming Ren, Ning Cao

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 7/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Cardiovascular death is the main cause of death in patients with end-stage kidney disease (ESKD). Left ventricular hypertrophy (LVH) and left atrial diameter (LAD) enlargement are frequent cardiac alterations in patients with ESKD and are major risk factors for cardiovascular events. However, it remains unclear whether there is an association between combined LAD or LVH and all-cause or cardiovascular mortality in this population.

Methods

A single-centre, retrospective cohort study including 576 haemodialysis (HD) patients was conducted. Patients were evaluated by cardiac ultrasound, and the study cohort was divided into four groups according to LAD and LVH status: low LAD and non-LVH; low LAD and LVH; high LAD and non-LVH; and high LAD and LVH. We used Kaplan–Meier analysis and Cox proportional hazard regression to analyse all-cause and cardiovascular mortality after multivariate adjustment.

Results

LAD was associated with an increased risk of all-cause mortality (HR 2.371, 1.602–3.509; p < 0.001). No significant differences were found between LVH and the risk of all-cause mortality. Patients with high LAD and LVH had significantly greater all-cause and cardiovascular mortality than did those with low LAD and non-LVH after adjustments for numerous potential confounders (HR 3.080, 1.608–5.899; p = 0.001) (HR 4.059, 1.753–9.397; p = 0.001).

Conclusion

Among maintenance haemodialysis (MHD) patients, LAD was more strongly associated with mortality than was LVH. A high LAD and LVH are associated with a greater risk of mortality. Our results emphasize that the occurrence of LAD and LVH in combination provides information that may be helpful in stratifying the risk of MHD patients.
Literatur
1.
Zurück zum Zitat Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int suppl. 2015;5(1):2–7.CrossRef Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int suppl. 2015;5(1):2–7.CrossRef
2.
Zurück zum Zitat LaTonya J, Hickson, Sara M, Negrotto, Macaulay O, Christopher G. Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating haeemodialysis. J Am Coll Cardiol. 2016;67(10):1173–82.CrossRef LaTonya J, Hickson, Sara M, Negrotto, Macaulay O, Christopher G. Echocardiography criteria for structural heart disease in patients with end-stage renal disease initiating haeemodialysis. J Am Coll Cardiol. 2016;67(10):1173–82.CrossRef
3.
Zurück zum Zitat Kessler M, Zannad F, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrol Dial Transplant. 2007;22(12):3573–9.CrossRefPubMed Kessler M, Zannad F, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrol Dial Transplant. 2007;22(12):3573–9.CrossRefPubMed
4.
Zurück zum Zitat Chen SC, Chang JM, Liu WC, Huang JC, Tsai JC, Lin MY, Su HM, Hwang SJ, Chen HC. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant. 2012;27(3):1064–70.CrossRefPubMed Chen SC, Chang JM, Liu WC, Huang JC, Tsai JC, Lin MY, Su HM, Hwang SJ, Chen HC. Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant. 2012;27(3):1064–70.CrossRefPubMed
5.
Zurück zum Zitat Mccullough PA, Roberts WC. Influence of chronic renal failure on cardiac structure. J Am Coll Cardiol. 2016;67(10):1183–5.CrossRefPubMed Mccullough PA, Roberts WC. Influence of chronic renal failure on cardiac structure. J Am Coll Cardiol. 2016;67(10):1183–5.CrossRefPubMed
6.
Zurück zum Zitat Zhu J, Tang C, Ouyang H, Shen H, You T, Hu J. Prediction of all-cause mortality using an echocardiography-based risk score in haeemodialysis patients. Cardiorenal Med. 2021;11(1):33–43.CrossRefPubMed Zhu J, Tang C, Ouyang H, Shen H, You T, Hu J. Prediction of all-cause mortality using an echocardiography-based risk score in haeemodialysis patients. Cardiorenal Med. 2021;11(1):33–43.CrossRefPubMed
7.
Zurück zum Zitat Tripepi G, Pannier B, D’Arrigo G, Mallamaci F, Zoccali C, London G. Reappraisal in two European cohorts of the prognostic power of left ventricular massindexin chronic kidney failure. Kidney Int. 2017;91(3):704–10.CrossRefPubMed Tripepi G, Pannier B, D’Arrigo G, Mallamaci F, Zoccali C, London G. Reappraisal in two European cohorts of the prognostic power of left ventricular massindexin chronic kidney failure. Kidney Int. 2017;91(3):704–10.CrossRefPubMed
8.
Zurück zum Zitat Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141(3):334–41.CrossRefPubMed Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141(3):334–41.CrossRefPubMed
9.
Zurück zum Zitat Bouzas-Mosquera A, Broullon FJ, Alvarez-Garcia N, Mendez E, Peteiro J, Gandara-Sambade T, Prada O, Mosquera VX, Castro-Beiras A. Left atrial size and risk for all-cause mortality and ischaemiemic stroke. CMAJ : Can Med Assoc J. 2011;183(10):E657-664.CrossRef Bouzas-Mosquera A, Broullon FJ, Alvarez-Garcia N, Mendez E, Peteiro J, Gandara-Sambade T, Prada O, Mosquera VX, Castro-Beiras A. Left atrial size and risk for all-cause mortality and ischaemiemic stroke. CMAJ : Can Med Assoc J. 2011;183(10):E657-664.CrossRef
10.
Zurück zum Zitat Devereux R. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8.CrossRefPubMed Devereux R. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8.CrossRefPubMed
11.
Zurück zum Zitat Chamber Quantification Writing G, American Society of Echocardiography’s.G, Standards C, European Association of E, Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRef Chamber Quantification Writing G, American Society of Echocardiography’s.G, Standards C, European Association of E, Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRef
12.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Boehm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRefPubMed Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Boehm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.CrossRefPubMed
13.
Zurück zum Zitat Quin Ones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15(2):167–84.CrossRef Quin Ones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002;15(2):167–84.CrossRef
14.
Zurück zum Zitat Lang RM, Bierig M, Devereux RB. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Qua. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRefPubMed Lang RM, Bierig M, Devereux RB. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Qua. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRefPubMed
15.
Zurück zum Zitat Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003;14(1):159–68.CrossRefPubMed Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003;14(1):159–68.CrossRefPubMed
16.
Zurück zum Zitat Parfrey PS, Foley RN, Harnett JD, Kent GM, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11(7):1277–85.CrossRefPubMed Parfrey PS, Foley RN, Harnett JD, Kent GM, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11(7):1277–85.CrossRefPubMed
17.
Zurück zum Zitat Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol. 1994;4(7):1486–90.CrossRefPubMed Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol. 1994;4(7):1486–90.CrossRefPubMed
18.
Zurück zum Zitat Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F, London GM. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50(2):600–8.CrossRefPubMed Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F, London GM. Cardiac and arterial interactions in end-stage renal disease. Kidney Int. 1996;50(2):600–8.CrossRefPubMed
19.
Zurück zum Zitat Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol. 1997;8(11):1764–70.CrossRefPubMed Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol. 1997;8(11):1764–70.CrossRefPubMed
20.
Zurück zum Zitat Ernesto P, Claudia S, Giovanni DM, Diego B, Beatrice D, Paolo C, Giuseppe C. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant. 2004;7:1829–34. Ernesto P, Claudia S, Giovanni DM, Diego B, Beatrice D, Paolo C, Giuseppe C. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant. 2004;7:1829–34.
21.
Zurück zum Zitat Foley RN, Parfrey PS, Kent GM, Harnett JD, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol. 2000;11(5):912–6.CrossRefPubMed Foley RN, Parfrey PS, Kent GM, Harnett JD, Barre PE. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol. 2000;11(5):912–6.CrossRefPubMed
22.
Zurück zum Zitat Zoccali C. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol. 2006;17(5):1460–5.CrossRefPubMed Zoccali C. Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study. J Am Soc Nephrol. 2006;17(5):1460–5.CrossRefPubMed
23.
Zurück zum Zitat London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759–67.CrossRefPubMed London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol. 2001;12(12):2759–67.CrossRefPubMed
24.
Zurück zum Zitat Trinh E, Chan CT. Intensive home hemodialysis results in regression of left ventricular hypertrophy and better clinical outcomes. Am J Nephrol. 2016;44(4):300–7.CrossRefPubMed Trinh E, Chan CT. Intensive home hemodialysis results in regression of left ventricular hypertrophy and better clinical outcomes. Am J Nephrol. 2016;44(4):300–7.CrossRefPubMed
25.
Zurück zum Zitat Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TSM. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol. 2006;47(12):2357–63.CrossRefPubMed Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TSM. Left atrial size: physiologic determinants and clinical applications. J Am Coll Cardiol. 2006;47(12):2357–63.CrossRefPubMed
26.
Zurück zum Zitat Patel DA, Lavie CJ, Milani RV, Shah S, Gilliland Y. Clinical implications of left atrial enlargement: a review. Ochsner J. 2009;9(4):191–6.PubMedPubMedCentral Patel DA, Lavie CJ, Milani RV, Shah S, Gilliland Y. Clinical implications of left atrial enlargement: a review. Ochsner J. 2009;9(4):191–6.PubMedPubMedCentral
27.
Zurück zum Zitat Kedia G, Habibzadeh MR, Kudithipudi V, Molls F, Sorrell VL. Using traditional measurements of the left atrial diameter to predict the left atrial volume index. Echocardiography. 2010;25(1):36–9.CrossRef Kedia G, Habibzadeh MR, Kudithipudi V, Molls F, Sorrell VL. Using traditional measurements of the left atrial diameter to predict the left atrial volume index. Echocardiography. 2010;25(1):36–9.CrossRef
28.
Zurück zum Zitat Jun KS, Hyeok HS, Tak PJ, Jwa-Kyung K, Jung OH, Eun YD, Tae-Hyun Y, Shin-Wook K, Hun CK. Left atrial volume is an independent predictor of mortality in CAPD patients. Nephrol Dial Transplant. 2011;11:3732–9. Jun KS, Hyeok HS, Tak PJ, Jwa-Kyung K, Jung OH, Eun YD, Tae-Hyun Y, Shin-Wook K, Hun CK. Left atrial volume is an independent predictor of mortality in CAPD patients. Nephrol Dial Transplant. 2011;11:3732–9.
29.
Zurück zum Zitat Agarwal R. (2012) Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant. 2012;27:3908–14.CrossRefPubMedPubMedCentral Agarwal R. (2012) Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant. 2012;27:3908–14.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Stosovic MD, Petrovic MZ, Vujisic-Tesic BD, Stanojevic ML, Naumovic RT. Predictive value of echocardiography and its relation to Kt/V and anthropometric parameters in hemodialysis patients. Ren Fail. 2015;37(4):1–8.CrossRef Stosovic MD, Petrovic MZ, Vujisic-Tesic BD, Stanojevic ML, Naumovic RT. Predictive value of echocardiography and its relation to Kt/V and anthropometric parameters in hemodialysis patients. Ren Fail. 2015;37(4):1–8.CrossRef
31.
Zurück zum Zitat Zhang M, Zhang L, Hu Y, Wang Y, Xu S, Xie X, Xu T, Li Z, Jin H, Liu H. Sarcopenia and echocardiographic parameters for prediction of cardiovascular events and mortality in patients undergoing maintenance hemodialysis. PeerJ. 2022;10: e14429.CrossRefPubMedPubMedCentral Zhang M, Zhang L, Hu Y, Wang Y, Xu S, Xie X, Xu T, Li Z, Jin H, Liu H. Sarcopenia and echocardiographic parameters for prediction of cardiovascular events and mortality in patients undergoing maintenance hemodialysis. PeerJ. 2022;10: e14429.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Qin Z, Yang Q, Yang M, Han M, Xiong Y, Liao R, Su B. Serum leptin concentration can predict cardiovascular outcomes and all-cause death in maintenance hemodialysis patients. Clin Chim Acta Int J Clin Chem. 2021;520:87–94.CrossRef Qin Z, Yang Q, Yang M, Han M, Xiong Y, Liao R, Su B. Serum leptin concentration can predict cardiovascular outcomes and all-cause death in maintenance hemodialysis patients. Clin Chim Acta Int J Clin Chem. 2021;520:87–94.CrossRef
33.
Zurück zum Zitat Vickery S, Price CP, Mbbchir RIJ, Abbas NA, Webb MC, Kempsonc ME, Lamb EJ. B-Type Natriuretic Peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46(4):610–20.CrossRefPubMed Vickery S, Price CP, Mbbchir RIJ, Abbas NA, Webb MC, Kempsonc ME, Lamb EJ. B-Type Natriuretic Peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46(4):610–20.CrossRefPubMed
34.
Zurück zum Zitat Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Kitazono T. Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients with chronic kidney disease. J Hypertens. 2016;34(4):753–61.CrossRefPubMed Yoshitomi R, Nakayama M, Sakoh T, Fukui A, Kitazono T. Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients with chronic kidney disease. J Hypertens. 2016;34(4):753–61.CrossRefPubMed
35.
Zurück zum Zitat Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. Fram Hear Study Circ. 1995;92(4):835–41.CrossRef Benjamin EJ, D’Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. Fram Hear Study Circ. 1995;92(4):835–41.CrossRef
36.
Zurück zum Zitat Szu-Chia C, Ho-Ming S, Yi-Chun T, Jiun-Chi H, Jer-Ming C, Shang-Jyh H, Hung-Chun C, Bruno C. Framingham risk score with cardiovascular events in chronic kidney disease. PLoS ONE. 2013;8(3): e60008.CrossRef Szu-Chia C, Ho-Ming S, Yi-Chun T, Jiun-Chi H, Jer-Ming C, Shang-Jyh H, Hung-Chun C, Bruno C. Framingham risk score with cardiovascular events in chronic kidney disease. PLoS ONE. 2013;8(3): e60008.CrossRef
37.
Zurück zum Zitat Unver S, Kavlak E, Gümüsel HK, Celikbilek F, Kirilmaz A. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients. Ren Fail. 2015;37(6):951–6.CrossRefPubMed Unver S, Kavlak E, Gümüsel HK, Celikbilek F, Kirilmaz A. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients. Ren Fail. 2015;37(6):951–6.CrossRefPubMed
38.
Zurück zum Zitat Park WY, Park S, Kim YW, Jin K. Clinical efficacy of biomarkers for evaluation of volume status in dialysis patients. Medicine. 2020;99(31): e21460.CrossRefPubMedPubMedCentral Park WY, Park S, Kim YW, Jin K. Clinical efficacy of biomarkers for evaluation of volume status in dialysis patients. Medicine. 2020;99(31): e21460.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Ozkahya M, Toz H, Qzerkan F, Duman S, Ok E, Basci A, Mees EJ. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol. 2002;15(6):655–60.PubMed Ozkahya M, Toz H, Qzerkan F, Duman S, Ok E, Basci A, Mees EJ. Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol. 2002;15(6):655–60.PubMed
Metadaten
Titel
Left ventricular hypertrophy and left atrial diameter are associated with mortality risk in haemodialysis patients: a retrospective cohort study
verfasst von
Jiuxu Bai
Wanqing Huang
Yanping Zhang
Lin Wei
Chen Zhao
Zhuo Ren
Qian Wang
Kaiming Ren
Ning Cao
Publikationsdatum
08.03.2024
Verlag
Springer Nature Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 7/2024
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-024-02480-z

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Dank Nasenspray seltener in die Notaufnahme

Durch die intranasale Applikation von Etripamil lassen sich paroxysmale supraventrikuläre Tachykardien (PSVT) oft in Eigenregie beenden. Das erspart den Betroffenen das Aufsuchen von Notfallambulanzen.

Vorhofflimmern: So häufig kommt es bei Katheterablation zu Embolien

Arterielle Embolien – insbesondere Hirnembolien - sind eine mögliche periprozedurale Komplikation bei Katheterablation von Vorhofflimmern. Wie hoch ist das Risiko? Eine Analyse von weltweit mehr als 300.000 Ablationsprozeduren gibt darüber Auskunft.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.